Evidence map›Paper›PMID 31914438›Full record

Trial reportMedical principles and practice : international journal of the Kuwait University, Health Science Centre2020

Intravoxel Incoherent Motion of Colon Cancer Liver Metastases for the Assessment of Response to Antiangiogenic Treatment: Results from a Pilot Study.

Ayşegül Öz, Sadık Server, Bedriye Koyuncu Sökmen, Esat Namal, Nagihan İnan, Numan Cem Balcı

Abstract readClinical Trial
In one paragraph

Trial report in Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ayşegül ÖzDepartment of Radiology, Faculty of Medicine, Istanbul Bilim University, Istanbul, Turkey, aoz.ayseguloz@gmail.com.
Sadık ServerDepartment of Radiology, Faculty of Medicine, Istanbul Bilim University, Istanbul, Turkey.
Bedriye Koyuncu SökmenDepartment of Radiology, Faculty of Medicine, Istanbul Bilim University, Istanbul, Turkey.
Esat NamalDepartment of Medical Oncology, Faculty of Medicine, Istanbul Bilim University, Istanbul, Turkey.
Nagihan İnanDepartment of Radiology, Faculty of Medicine, Istanbul Bilim University, Istanbul, Turkey.
Numan Cem BalcıDepartment of Radiology, Cleveland Clinic, Lerner School of Medicine, Abu Dhabi, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study was aimed at evaluating the intravoxel incoherent motion (IVIM) parameter alterations of liver metastases of colorectal carcinoma (CRC) during antiangiogenic bevacizumab combination therapy.

methodsTwenty-five patients with CRC liver metastases treated with bevacizumab in combination with FOLFOX-or-FOLFIRI protocols were enrolled in the study. MRI was performed using a 1.5-tesla scanner pre-treatment (PT) and at 3, 6, and 9 months of therapy. Routine abdominal MRI sequences and an IVIM-DWI (diffusion-weighted imaging) sequence were obtained. The IVIM-DWI sequence was executed with 16 b-values varying from 0 to 1,400 s/mm2. The mean values of apparent diffusion coefficient (ADC), true diffusion (D), pseudodiffusion (D*), and perfusion fraction (f) of each metastasis were obtained for all b-values, and the time-related changes were recorded to analyze the chronologic responses to antiangiogenic therapy. The RECIST 1.1 criteria were used for the evaluation of treatment response.

resultsThe diameters of the metastases diminished significantly at 9 months when compared with PT (p = 0.03). The D (p = 0.10) and ADC (p = 0.21) values of the metastases increased at 9 months of therapy. D* was the highest at 3 months (p =0.24); it decreased at 6 (p =0.97) and 9 months (p =0.87) of therapy. The f value had peaked at 3 months (p =0.51) and started to decrease thereafter. At 6 months, f decreased to the lowest values (p =0.12).

conclusionIVIM parameters, particularly the perfusion fraction, may quantitatively reflect the response to antiangiogenic treatment. The antiangiogenic response manifests after 3 months of therapy before the RECIST-related response.

Indexed as

AdultAngiogenesis InhibitorsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCamptothecinColonic NeoplasmsDiffusion Magnetic Resonance ImagingFemaleFluorouracilHumansLeucovorinLiver NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsAngiogenesis InhibitorsAntineoplastic Agents, ImmunologicalBevacizumabCamptothecinFluorouracilLeucovorinOrganoplatinum CompoundsBevacizumabColorectal carcinoma metastasisDiffusion-weighted MRIIntravoxel incoherent motion

Identifiers

PMID31914438
PMCPMC7511688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.